Safety and efficacy of human Wharton's Jelly-derived mesenchymal stem cells therapy for retinal degeneration

• Main Authors: Leow, S. N., Luu, Chi D., Hairul Nizam, M. H., Mok, Pooi Ling, Ruhaslizan, R., Wong, H. S., Wan Abdul Halim, Wan Haslina, Ng, M. H., Ruszymah, B. H. I., Chowdhury, S. R., Bastion, M. L. C., Then, K. Y.
• 格式: Article
• 语言: English
• 出版: Public Library of Science 2015
• 在线阅读: http://psasir.upm.edu.my/id/eprint/46215/1/Safety%20and%20efficacy%20of%20human%20Wharton%27s%20Jelly-derived%20mesenchymal%20stem%20cells%20therapy%20for%20retinal%20degeneration.PDF; http://psasir.upm.edu.my/id/eprint/46215/

Purpose To investigate the safety and efficacy of subretinal injection of human Wharton’s Jelly-derived mesenchymal stem cells (hWJ-MSCs) on retinal structure and function in Royal College of Surgeons (RCS) rats. Methods RCS rats were divided into 2 groups: hWJ-MSCs treated group (n = 8) and placebo control group (n = 8). In the treatment group, hWJ-MSCs from healthy donors were injected into the subretinal space in one eye of each rat at day 21. Control group received saline injection of the same volume. Additional 3 animals were injected with nanogold-labelled stem cells for in vivo tracking of cells localisation using a micro-computed tomography (microCT). Retinal function was assessed by electroretinography (ERG) 3 days before the injection and repeated at days 15, 30 and 70 after the injection. Eyes were collected at day 70 for histology, cellular and molecular studies. Results No retinal tumor formation was detected by histology during the study period. MicroCT scans showed that hWJ-MSCs stayed localised in the eye with no systemic migration. Transmission electron microscopy showed that nanogold-labelled cells were located within the subretinal space. Histology showed preservation of the outer nuclear layer (ONL) in the treated group but not in the control group. However, there were no significant differences in the ERG responses between the groups. Confocal microscopy showed evidence of hWJ-MSCs expressing markers for photoreceptor, Müller cells and bipolar cells. Conclusions Subretinal injection of hWJ-MSCs delay the loss of the ONL in RCS rats. hWJ-MSCs appears to be safe and has potential to differentiate into retinal-like cells. The potential of this cell-based therapy for the treatment of retinal dystrophies warrants further studies.